Identification of differentially secreted biomarkers using LC-MS/MS in isogenic cell lines representing a progression of breast cancer

Journal of Proteome Research

Volumn 6, Issue 8, 2007, Pages 2993-3002

  Mbeunkui, Flaubert ^a   Metge, Brandon J ^a   Shevde, Lalita A ^a   Pannell, Lewis K ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

Alpha 1 antichymotrypsin; Breast cancer; Galectin 3 binding protein; LC MS MS; Mass spectrometry; MCF10; Nonclassical secretion; Proteomics; Secreted proteins; Secretome

Indexed keywords

ACTIN; ALPHA 1 ANTICHYMOTRYPSIN; BIOLOGICAL MARKER; CATHEPSIN D; GALECTIN 3; PROTEIN LYSINE 6 OXIDASE; PROTEIN S 100; PROTEOME; TUBULIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENICITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING;

BREAST NEOPLASMS; CELL LINE; CHROMATOGRAPHY, LIQUID; DISEASE PROGRESSION; FEMALE; HUMANS; PROTEOME; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 34548182124     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr060629m     Document Type: Article

References (81)

1. Flagg, E. W., et al. Validation of the American Cancer Society Cancer Prevention Study II Nutrition Survey Cohort Food Frequency Questionnaire. Epidemiology 2000, 11 (4), 462-8.
2. Ruoslahti, E. Fibronectin and its integrin receptors in cancer. Adv. Cancer Res. 1999, 76, 1-20.
3. Mbeunkui, F.; Fodstad, O.; Pannell, L. K. Secretory protein enrichment and analysis: an optimized approach applied on cancer cell lines using 2D LC-MS/MS. J. Proteome Res. 2006, 5 (4), 899-906.
4. Hunter, T. Oncoprotein networks. Cell 1997, 88 (3), 333-46.
5. Dwek, M. V.; Alaiya, A. A. Proteome analysis enables separate clustering of normal breast, benign breast and breast cancer tissues. Br. J. Cancer 2003, 89 (2), 305-7.
6. Porter, D. A., et al. A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res. 2001, 61 (15), 5697-702.
7. Porter, D., et al. Molecular markers in ductal carcinoma in situ of the breast. Mol. Cancer Res. 2003, 1 (5), 362-75.
8. Anderson, L.; Seilhamer, J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 1997, 18 (3-4), 533-7.
9. Chambers, G., et al. Proteomics: a new approach to the study of disease. J. Pathol. 2000, 192 (3), 280-8.
10. Liu, H.; Sadygov, R. G.; Yates, J. R., 3rd. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal. Chem. 2004, 76 (14), 4193-201.
11. Miller, F. R., et al. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J. Natl. Cancer Inst. 2000, 92 (14), 1185-6.
12. Santner, S. J., et al. Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res. Treat. 2001, 65 (2), 101-10.
13. Strickland, L. B., et al. Progression of premalignant MCF10AT generates heterogeneous malignant variants with characteristic histologic types and immunohistochemical markers. Breast Cancer Res. Treat. 2000, 64 (3), 235-40.
14. Naundorf, H., et al. Characterization of two human mammary carcinomas, MT-1 and MT-3, suitable for in vivo testing of ether lipids and their derivatives. Breast Cancer Res. Treat. 1992, 23 (1-2), 87-95.
15. Boja, E. S.; Fales, H. M. Overalkylation of a protein digest with iodoacetamide. Anal. Chem. 2001, 73 (15), 3576-82.
16. Ho, M., et al. Mesothelin is shed from tumor cells. Cancer Epidemiol. Biomarkers Prev. 2006, 15 (9), 1751.
17. Aebersold, R.; Mann, M. Mass spectrometry-based proteomics. Nature 2003, 422 (6928), 198-207.
18. Iacobelli, S., et al. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res. 1986, 46 (6), 3005-10.
19. Bair, E. L., et al. 90K/Mac-2 binding protein is expressed in prostate cancer and induces promatrilysin expression. Prostate 2006, 66 (3), 283-93.
20. Ulmer, T. A., et al. Tumor-associated antigen 90K/Mac-2-binding protein: possible role in colon cancer. J. Cell Biochem. 2006, 98 (5), 1351-66.
21. Chawla, R. K., et al. Serum alpha-1 proteinase inhibitor in advanced cancer: mass variants and functionally inert forms. Cancer Res. 1987, 47 (4), 1179-84.
22. Tountas, Y., et al. Alpha 1-antitrypsin and cancer of the pancreas. Digestion 1985, 31 (1), 37-40.
23. Travis, J.; Salvesen, G. S. Human plasma proteinase inhibitors. Annu. Rev. Biochem. 1983, 52, 655-709.
24. Isaacson, P., et al. Alpha-1-antitrypsin in human macrophages. J. Clin. Pathol. 1981, 34 (9), 982-90.
25. Kataoka, H., et al. Properties of alpha 1-antitrypsin secreted by human adenocarcinoma cell lines. FEBS Lett. 1993, 328 (3), 291-5.
26. Perlmutter, D. H., et al. Expression of the alpha 1-proteinase inhibitor gene in human monocytes and macrophages. Proc. Natl. Acad. Sci. U.S.A. 1985, 82 (3), 795-9.
27. Zelvyte, I.; Lindgren, S.; Janciauskiene, S. Multiple effects of alpha1-antitrypsin on breast carcinoma MDA-MB 468 cell growth and invasiveness. Eur. J. Cancer Prev. 2003, 12 (2), 117-24.
28. Kuvibidila, S.; Rayford, W. Correlation between serum prostate-specific antigen and alpha-1-antitrypsin in men without and with prostate cancer. J. Lab. Clin. Med. 2006, 147 (4), 174-81.
29. Zhang, W. M., et al. Measurement of the complex between prostate-specific antigen and alphal-protease inhibitor in serum. Clin. Chem. 1999, 45 (6 Pt 1), 814-21.
30. Van Molle, W., et al. Alpha 1-acid glycoprotein and alpha 1-antitrypsin inhibit TNF-induced but not anti-Fas-induced apoptosis of hepatocytes in mice. J. Immunol. 1997, 159 (7), 3555-64.
31. Higashiyama, M., et al. Alpha-1-antichymotrypsin expression in lung adenocarcinoma and its possible association with tumor progression. Cancer 1995, 76 (8), 1368-76.
32. Laursen, I.; Lykkesfeldt, A. E. Purification and characterization of an alpha 1-antichymotrypsin-like 66 kDa protein from the human breast cancer cell line, MCF-7. Biochim. Biophys. Acta 1992, 1121 (1-2), 119-29.
33. Kennedy, A. R. Chemopreventive agents: protease inhibitors. Pharmacol. Ther. 1998, 78 (3), 167-209.
34. Watkins, G., et al. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukotrienes Essent. Fatty Acids 2005, 72 (4), 267-72.
35. Bellahcene, A.; Castronovo, V. Expression of bone matrix proteins in human breast cancer: potential roles in microcalcification formation and in the genesis of bone metastases. Bull. Cancer 1997, 84 (1), 17-24.
36. Jacob, K., et al. Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res. 1999, 59 (17), 4453-7.
37. Campo McKnight, D. A., et al. Roles of osteonectin in the migration of breast cancer cells into bone. J. Cell Biochem. 2006, 97 (2), 288-302.
38. Gilles, C., et al. SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res. 1998, 58 (23), 5529-36.
39. Argani, P., et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin. Cancer Res. 2001, 7 (12), 3862-8.
40. Chang, K.; Pastan, I.; Willingham, M. C. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int. J. Cancer 1992, 50 (3), 373-81.
41. Hassan, R., et al. Localization of mesothelin in epithelial ovarian cancer. Appl. Immunohistochem. Mol. Morphol. 2005, 13 (3), 243-7.
42. Hassan, R., et al. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am. J. Clin. Pathol. 2005, 124 (6), 838-45.
43. Ordonez, N. G. Application of mesothelin immunostaining in tumor diagnosis. Am. J. Surg. Pathol. 2003, 27 (11), 1418-28.
44. Thomas, A. M., et al. Mesothelin-specific CD8 (+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J. Exp. Med. 2004, 200 (3), 297-306.
45. Hassan, R.; Bera, T.; Pastan, I. Mesothelin: a new target for immunotherapy. Clin. Cancer Res. 2004, 10 (12 Pt 1), 3937-42.
46. Onda, M., et al. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin. Cancer Res. 2006, 12 (14 Pt 1), 4225-31.
47. Yamaguchi, N., et al. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J. Biol. Chem. 1994, 269 (2), 805-8.
48. Lloyd, K. O.; Yin, B. W. Synthesis and secretion of the ovarian cancer antigen CA 125 by the human cancer cell line NIH:OVCAR-3. Tumour Biol. 2001, 22 (2), 77-82.
49. Yin, B. W.; Lloyd, K. O. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J. Biol. Chem. 2001, 276 (29), 27371-5.
50. Hassan, R., et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin. Cancer Res. 2006, 12 (2), 447-53.
51. Yen, M. J., et al. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin. Cancer Res. 2006, 12 (3 Pt 1), 827-31.
52. Kirschmann, D. A., et al. A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res. 2002, 62 (15), 4478-83.
53. Payne, S. L., et al. Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism. Cancer Res. 2005, 65 (24), 11429-36.
54. Erler, J. T.; Giaccia, A. J. Lysyl oxidase mediates hypoxic control of metastasis. Cancer Res. 2006, 66 (21), 10238-41.
55. Erler, J. T., et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006, 440 (7088), 1222-6.
56. Hale, L. P., et al. Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer. Clin. Cancer Res. 2001, 7 (4), 846-53.
57. Bundred, N. J., et al. Zinc alpha-2 glycoprotein levels in serum and breast fluids: a potential marker of apocrine activity. Eur. J. Cancer 1991, 27 (5), 549-52.
58. Barrett, A. J. Cathepsin, D. Purification of isoenzymes from human and chicken liver. Biochem. J. 1970, 117 (3), 601-7.
59. Diment, S.; Martin, K. J.; Stahl, P. D. Cleavage of parathyroid hormone in macrophage endosomes illustrates a novel pathway for intracellular processing of proteins. J. Biol. Chem. 1989, 264 (23), 13403-6.
60. Capony, F., et al. Increased secretion, altered processing, and glycosylation of pro-cathepsin D in human mammary cancer cells. Cancer Res. 1989, 49 (14), 3904-9.
61. Rochefort, H. Cathepsin D in breast cancer: a tissue marker associated with metastasis. Eur. J. Cancer 1992, 28A (11), 1780-3.
62. Westley, B. R.; May, F. E. Prognostic value of cathepsin D in breast cancer. Br. J. Cancer. 1999, 79 (2), 189-90.
63. Liaudet-Coopman, E., et al. Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. Cancer Lett. 2006, 237 (2), 167-79.
64. Basset, P., et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990, 348 (6303), 699-704.
65. Uria, J. A., et al. Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions. Cancer Res. 1997, 57 (21), 4882-8.
66. Christensen, L., et al. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha (2)-macroglobulin receptor in human breast carcinomas. Int. J. Cancer 1996, 66 (4), 441-52.
67. Emberley, E. D.; Murphy, L. C.; Watson, P. H. S100A7 and the progression of breast cancer. Breast Cancer Res. 2004, 6 (4), 153-9.
68. Sherbet, G. V.; Lakshmi, M. S. S100A4 (MTS1) calcium binding protein in cancer growth, invasion and metastasis. Anticancer Res. 1998, 18 (4A), 2415-21.
69. Danielsen, E. M.; van Deurs, B.; Hansen, G. H. "Nonclassical" secretion of annexin A2 to the lumenal side of the enterocyte brush border membrane. Biochemistry 2003, 42 (49), 14670-6.
70. Deora, A. B., et al. An annexin 2 phosphorylation switch mediates p11-dependent translocation of annexin 2 to the cell surface. J. Biol. Chem. 2004, 279 (42), 43411-8.
71. Chasserot-Golaz, S., et al. Annexin 2 promotes the formation of lipid microdomains required for calcium-regulated exocytosis of dense-core vesicles. Mol. Biol. Cell 2005, 16 (3), 1108-19.
72. Espana, L., et al. Bcl-x (L)-mediated changes in metabolic pathways of breast cancer cells: from survival in the blood stream to organ-specific metastasis. Am. J. Pathol. 2005, 167 (4), 1125-37.
73. Pancholi, V. Multifunctional alpha-enolase: its role in diseases. Cell Mol. Life Sci. 2001, 58 (7), 902-20.
74. Lopez-Alemany, R., et al. Inhibition of cell surface mediated plasminogen activation by a monoclonal antibody against alpha-Enolase. Am. J. Hematol. 2003, 72 (4), 234-42.
75. Neubauer, H., et al. Breast cancer proteomics by laser capture microdissection, sample pooling, 54-cm IPG IEF, and differential iodine radioisotope detection. Electrophoresis 2006, 27 (9), 1840-52.
76. Mikuriya, K., et al. Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int. J. Oncol. 2007, 30 (4), 849-55.
77. Li, M., et al. Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147. Cancer 2006, 106 (10), 2284-94.
78. Choi, K. J., et al. Overexpressed cyclophilin a in cancer cells renders resistance to hypoxia- and Cisplatin-induced cell death. Cancer Res. 2007, 67 (8), 3654-62.
79. Gonzalez-Santiago, L., et al. Proteomic analysis of the resistance to aplidin in human cancer cells. J. Proteome Res. 2007, 6 (4), 1286-94.
80. Huang, C. M., et al. Mass spectrometric proteomics profiles of in vivo tumor secretomes: capillary ultrafiltration sampling of regressive tumor masses. Proteomics 2006, 6 (22), 6107-16.
81. Li, D. Q., et al. Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry. Proteomics 2006, 6 (11), 3352-68.